Lexaria Net Income From Continuing Ops from 2010 to 2024

LEXX Stock  USD 2.13  0.02  0.93%   
Lexaria Bioscience Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -6.3 M in 2024. During the period from 2010 to 2024, Lexaria Bioscience Net Loss regression line of annual values had significance of  0.000067 and arithmetic mean of (3,933,560). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-6 M
Current Value
-6.3 M
Quarterly Volatility
2.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 132.7 K, Interest Expense of 107.8 K or Other Operating Expenses of 8.2 M, as well as many indicators such as Price To Sales Ratio of 110, Dividend Yield of 0.0 or PTB Ratio of 57.61. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.
  
Check out the analysis of Lexaria Bioscience Correlation against competitors.

Latest Lexaria Bioscience's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Lexaria Bioscience Corp over the last few years. It is Lexaria Bioscience's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexaria Bioscience's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Lexaria Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(3,933,560)
Coefficient Of Variation(54.89)
Mean Deviation1,870,489
Median(4,084,613)
Standard Deviation2,159,292
Sample Variance4.7T
Range5.5M
R-Value(0.85)
Mean Square Error1.4T
R-Squared0.72
Significance0.000067
Slope(409,083)
Total Sum of Squares65.3T

Lexaria Net Income From Continuing Ops History

2024-6.3 M
2023-6 M
2022-6.7 M
2021-7.4 M
2020-4.2 M
2019-4.1 M
2018-4.2 M

About Lexaria Bioscience Financial Statements

Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-6 M-6.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.